Insights

Strategic partnerships InnoCore’s unique SynBiosys biodegradable polymer technologies and focus on collaborations and licensing indicate strong potential for co-development and technology licensing deals with mid to large pharma players seeking long-acting injectable solutions.

Clinical development focus The company specializes in long acting and minimally invasive injectable delivery for peptides and biologics, signaling opportunities to engage early with API manufacturers and biotech firms pursuing stable, scalable formulations for high-value biologics.

Global event presence Active participation in major life sciences conferences (BIO International, NLSDays, DDF Summit, Swiss Biotech Day, Bio-Europe Spring) presents multiple channels for face‑to‑face outreach, partnerships, and quick qualification of potential clients.

SMB to niche market With a revenue profile under $1M and 51–200 employees, InnoCore sits in a niche where tailored, pliable service packages and flexible pilot programs can convert small biotechs and mid-sized companies seeking scalable long‑acting solutions.

Expansion-ready portfolio A broad polymer platform enabling controlled release from days to six months and compatibility with small needle sizes highlights opportunities to upsell process development, scale‑up manufacturing, and device integration for injectable and implantable products.

Similar companies to Innocore

Innocore Tech Stack

Innocore uses 8 technology products and services including Google Ads, Microsoft Advertising, Hotjar, and more. Explore Innocore's tech stack below.

Media & News

Innocore's Email Address Formats

Innocore uses at least 2 email formats:
Innocore Email FormatsExamplePercentage
First@innocorepharma.comJohn@innocorepharma.com
93%
First.Last@innocorepharma.comJohn.Doe@innocorepharma.com
7%

Frequently Asked Questions

What is Innocore's official website and social media links?

Minus sign iconPlus sign icon
Innocore's official website is innocorepharma.com and has social profiles on LinkedIn.

How much revenue does Innocore generate?

Minus sign iconPlus sign icon
As of October 2026, Innocore's annual revenue is estimated to be <$1M.

What is Innocore's SIC code and NAICS code?

Minus sign iconPlus sign icon
Innocore's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Innocore have currently?

Minus sign iconPlus sign icon
As of October 2026, Innocore has approximately 59 employees across 3 continents, including Europe, North America and Asia. Key team members include Ceo: H. D. B., Chief Business Officer: M. B. and Chief Operating Officer: B. K. Explore Innocore's employee directory with LeadIQ.

What industry does Innocore belong to?

Minus sign iconPlus sign icon
Innocore operates in the Pharmaceutical Manufacturing industry.

What technology does Innocore use?

Minus sign iconPlus sign icon
Innocore's tech stack includes Google Ads, Microsoft Advertising, Hotjar, Amazon Web Services, WordPress, Cookiebot, Microsoft 365 and Tawk.to.

What is Innocore's email format?

Minus sign iconPlus sign icon
Innocore's email format typically follows the pattern of First@innocorepharma.com. Find more Innocore email formats with LeadIQ.

When was Innocore founded?

Minus sign iconPlus sign icon
Innocore was founded in 2003.
Innocore logo

Innocore

Pharmaceutical ManufacturingGroningen, Netherlands51-200 Employees

Innocore is a pharmaceutical manufacturing company based in Groningen, Netherlands, specializing in the formulation, process development, and manufacturing of long-acting and minimally invasive injectable drug delivery systems for peptide and biologic therapeutics. It provides a tunable polymer platform designed to control the release and performance of active pharmaceutical ingredients, including small molecules and biologics. Through development collaborations and licensing with SynBiosys biodegradable polymer technologies, Innocore aims to generate injectable and implantable products that extend treatment possibilities.

The platform addresses challenges such as toxicity, stability of sensitive compounds, and the need for controlled bioavailability by enabling low-temperature manufacturing and sustained release over days to six months. It offers precise control over particle size to improve injectability and reduce macrophage uptake, while supporting smooth bioavailability and the use of small needle sizes for patient comfort. The company positions its services for pharmaceutical and device developers pursuing long-acting injectable formulations.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2003
Employees
51-200

Section iconFunding & Financials

  • <$1M

    Innocore's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.